UA68365C2 - Peroral contraception by combination of anti-estrogen and progestin - Google Patents

Peroral contraception by combination of anti-estrogen and progestin Download PDF

Info

Publication number: UA68365C2
Authority: UA; Ukraine
Prior art keywords: ethoxy; benzyl; methyl; indol; piperidin
Prior art date: 1997-11-06

Application number

UA2000063196A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-11-06

Filing date

1998-04-11

Publication date

2004-08-16

1998-04-11 Application filed by Wyeth Corp filed Critical Wyeth Corp

2004-08-16 Publication of UA68365C2 publication Critical patent/UA68365C2/uk

Links

RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 title claims abstract description 39
239000000328 estrogen antagonist Substances 0.000 title claims abstract description 36
229940046836 anti-estrogen Drugs 0.000 title claims abstract description 35
230000001833 anti-estrogenic effect Effects 0.000 title claims abstract description 35
230000000708 anti-progestin effect Effects 0.000 title claims 2
239000003418 antiprogestin Substances 0.000 title claims 2
239000000583 progesterone congener Substances 0.000 claims abstract description 42
238000000034 method Methods 0.000 claims abstract description 17
230000027758 ovulation cycle Effects 0.000 claims abstract description 9
125000004432 carbon atom Chemical group C* 0.000 claims description 50
150000003839 salts Chemical class 0.000 claims description 37
WWYNJERNGUHSAO-XUDSTZEESA-N (+)-Norgestrel Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 WWYNJERNGUHSAO-XUDSTZEESA-N 0.000 claims description 19
229960004400 levonorgestrel Drugs 0.000 claims description 19
-1 Z-ketodesogestrel Chemical compound 0.000 claims description 18
229910052736 halogen Inorganic materials 0.000 claims description 18
150000002367 halogens Chemical class 0.000 claims description 18
125000003545 alkoxy group Chemical group 0.000 claims description 14
125000000000 cycloalkoxy group Chemical group 0.000 claims description 14
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 13
125000004093 cyano group Chemical group *C#N 0.000 claims description 13
239000003433 contraceptive agent Substances 0.000 claims description 11
125000000217 alkyl group Chemical group 0.000 claims description 10
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
229910052799 carbon Inorganic materials 0.000 claims description 7
150000001875 compounds Chemical class 0.000 claims description 7
230000002254 contraceptive effect Effects 0.000 claims description 7
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 6
229910052739 hydrogen Inorganic materials 0.000 claims description 6
229940053934 norethindrone Drugs 0.000 claims description 6
VIKNJXKGJWUCNN-XGXHKTLJSA-N norethisterone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 VIKNJXKGJWUCNN-XGXHKTLJSA-N 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
IMONTRJLAWHYGT-ZCPXKWAGSA-N Norethindrone Acetate Chemical compound C1CC2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@](C#C)(OC(=O)C)[C@@]1(C)CC2 IMONTRJLAWHYGT-ZCPXKWAGSA-N 0.000 claims description 5
229960000978 cyproterone acetate Drugs 0.000 claims description 5
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 claims description 5
229960004976 desogestrel Drugs 0.000 claims description 5
RPLCPCMSCLEKRS-BPIQYHPVSA-N desogestrel Chemical compound C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 RPLCPCMSCLEKRS-BPIQYHPVSA-N 0.000 claims description 5
AZFLJNIPTRTECV-FUMNGEBKSA-N dienogest Chemical compound C1CC(=O)C=C2CC[C@@H]([C@H]3[C@@](C)([C@](CC3)(O)CC#N)CC3)C3=C21 AZFLJNIPTRTECV-FUMNGEBKSA-N 0.000 claims description 5
229960003309 dienogest Drugs 0.000 claims description 5
METQSPRSQINEEU-UHFFFAOYSA-N dihydrospirorenone Natural products CC12CCC(C3(CCC(=O)C=C3C3CC33)C)C3C1C1CC1C21CCC(=O)O1 METQSPRSQINEEU-UHFFFAOYSA-N 0.000 claims description 5
229960004845 drospirenone Drugs 0.000 claims description 5
METQSPRSQINEEU-HXCATZOESA-N drospirenone Chemical compound C([C@]12[C@H]3C[C@H]3[C@H]3[C@H]4[C@@H]([C@]5(CCC(=O)C=C5[C@@H]5C[C@@H]54)C)CC[C@@]31C)CC(=O)O2 METQSPRSQINEEU-HXCATZOESA-N 0.000 claims description 5
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
229960001652 norethindrone acetate Drugs 0.000 claims description 5
KIQQMECNKUGGKA-NMYWJIRASA-N norgestimate Chemical compound O/N=C/1CC[C@@H]2[C@H]3CC[C@](CC)([C@](CC4)(OC(C)=O)C#C)[C@@H]4[C@@H]3CCC2=C\1 KIQQMECNKUGGKA-NMYWJIRASA-N 0.000 claims description 5
229960000417 norgestimate Drugs 0.000 claims description 5
JUNDJWOLDSCTFK-MTZCLOFQSA-N trimegestone Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@@](C(=O)[C@@H](O)C)(C)[C@@]1(C)CC2 JUNDJWOLDSCTFK-MTZCLOFQSA-N 0.000 claims description 5
229950008546 trimegestone Drugs 0.000 claims description 5
125000003710 aryl alkyl group Chemical group 0.000 claims description 4
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 4
150000003973 alkyl amines Chemical class 0.000 claims description 3
125000005842 heteroatom Chemical group 0.000 claims description 3
ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 claims description 2
JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 claims description 2
JEYWNNAZDLFBFF-UHFFFAOYSA-N Nafoxidine Chemical compound C1CC2=CC(OC)=CC=C2C(C=2C=CC(OCCN3CCCC3)=CC=2)=C1C1=CC=CC=C1 JEYWNNAZDLFBFF-UHFFFAOYSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
229950004203 droloxifene Drugs 0.000 claims description 2
229950002248 idoxifene Drugs 0.000 claims description 2
QZUHFMXJZOUZFI-ZQHSETAFSA-N miproxifene phosphate Chemical compound C=1C=C(C(C)C)C=CC=1C(/CC)=C(C=1C=CC(OP(O)(O)=O)=CC=1)\C1=CC=C(OCCN(C)C)C=C1 QZUHFMXJZOUZFI-ZQHSETAFSA-N 0.000 claims description 2
229950002366 nafoxidine Drugs 0.000 claims description 2
229960004622 raloxifene Drugs 0.000 claims description 2
GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims description 2
229960005026 toremifene Drugs 0.000 claims description 2
XFCLJVABOIYOMF-QPLCGJKRSA-N toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 claims description 2
125000004953 trihalomethyl group Chemical group 0.000 claims description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims 19
125000005099 aryl alkyl carbonyl group Chemical group 0.000 claims 4
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
229940022663 acetate Drugs 0.000 claims 3
GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical compound O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 claims 2
125000004429 atom Chemical group 0.000 claims 1
238000012876 topography Methods 0.000 claims 1
230000001836 utereotrophic effect Effects 0.000 abstract description 2
230000002354 daily effect Effects 0.000 description 9
229940127234 oral contraceptive Drugs 0.000 description 8
239000003539 oral contraceptive agent Substances 0.000 description 8
208000032843 Hemorrhage Diseases 0.000 description 4
230000000740 bleeding effect Effects 0.000 description 4
229940124558 contraceptive agent Drugs 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
210000004696 endometrium Anatomy 0.000 description 4
229940011871 estrogen Drugs 0.000 description 4
239000000262 estrogen Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
206010046788 Uterine haemorrhage Diseases 0.000 description 2
206010046910 Vaginal haemorrhage Diseases 0.000 description 2
210000003756 cervix mucus Anatomy 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001788 irregular Effects 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
239000003826 tablet Substances 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 1
VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
102000006771 Gonadotropins Human genes 0.000 description 1
108010086677 Gonadotropins Proteins 0.000 description 1
206010047998 Withdrawal bleed Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000002513 anti-ovulatory effect Effects 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000001174 ascending effect Effects 0.000 description 1
230000002051 biphasic effect Effects 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
125000000753 cycloalkyl group Chemical group 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
229960002258 fulvestrant Drugs 0.000 description 1
239000002622 gonadotropin Substances 0.000 description 1
229940094892 gonadotropins Drugs 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
238000002513 implantation Methods 0.000 description 1
231100000546 inhibition of ovulation Toxicity 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003217 oral combined contraceptive Substances 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

UA2000063196A 1997-11-06 1998-04-11 Peroral contraception by combination of anti-estrogen and progestin UA68365C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US96508397A	1997-11-06	1997-11-06
PCT/US1998/023427 WO1999024027A2 (en)	1997-11-06	1998-11-04	Anti-estrogen plus progestin containing oral contraceptives

Publications (1)

Publication Number	Publication Date
UA68365C2 true UA68365C2 (en)	2004-08-16

Family

ID=25509417

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2000063196A UA68365C2 (en)	1997-11-06	1998-04-11	Peroral contraception by combination of anti-estrogen and progestin

Country Status (28)

Country	Link
EP (1)	EP1051179B1 (cs)
JP (1)	JP2001522798A (cs)
CN (1)	CN1278732A (cs)
AR (1)	AR016667A1 (cs)
AT (1)	ATE304359T1 (cs)
AU (2)	AU760540B2 (cs)
BG (1)	BG104451A (cs)
BR (1)	BR9813982A (cs)
CA (1)	CA2307210A1 (cs)
CZ (1)	CZ294155B6 (cs)
DE (1)	DE69831605T2 (cs)
DK (1)	DK1051179T3 (cs)
EA (1)	EA200000492A1 (cs)
EE (1)	EE04092B1 (cs)
ES (1)	ES2246541T3 (cs)
GE (1)	GEP20043290B (cs)
HR (1)	HRP20000269A2 (cs)
HU (1)	HUP0100293A3 (cs)
ID (1)	ID24568A (cs)
IL (1)	IL135621A0 (cs)
NO (1)	NO20002167L (cs)
NZ (1)	NZ503890A (cs)
PL (1)	PL340623A1 (cs)
SK (1)	SK6482000A3 (cs)
TR (1)	TR200001268T2 (cs)
UA (1)	UA68365C2 (cs)
WO (1)	WO1999024027A2 (cs)
ZA (1)	ZA9810136B (cs)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120263A0 (en) *	1996-02-28	1997-06-10	Pfizer	Combination therapy to prevent bone loss-progesterone and estrogen agonists
HRP20000778B1 (en) *	1998-05-15	2004-10-31	Wyeth Corp	2-phenyl-1-/4-(2-aminoethoxy)-benzyl/-indole in combination with estrogens
US6479535B1 (en)	1998-05-15	2002-11-12	Wyeth	2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
NZ517645A (en) *	1999-09-13	2003-09-26	Wyeth Corp	Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1- [4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6380166B1 (en)	1999-09-13	2002-04-30	American Home Products Corporation	Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6376486B1 (en)	2000-07-06	2002-04-23	American Home Products Corporation	Methods of inhibiting sphincter incontinence
SK622004A3 (en)	2001-07-31	2004-08-03	Pfizer Prod Inc	Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists/antagonists, estrogens and progestins
AU2005302706B2 (en) *	2004-10-27	2011-12-15	Janssen Pharmaceutica N.V.	Indole derivatives useful as progesterone receptor modulators
FR2880625B1 (fr) *	2005-01-07	2007-03-09	Sanofi Aventis Sa	Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) *	2005-05-13	2006-12-29	Schering Ag	Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) *	2008-11-11	2010-05-12	Bayer Schering Pharma Aktiengesellschaft	Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
BR112012031464A2 (pt)	2010-06-10	2020-08-04	Aragon Pharmaceuticals, Inc.	moduladores do receptor de estrogênio e os seus usos
SG11201403002RA (en)	2011-12-14	2014-07-30	Seragon Pharmaceuticals Inc	Fluorinated estrogen receptor modulators and uses thereof
KR102710603B1 (ko)	2015-10-01	2024-09-27	올레마 파마슈티컬스 인코포레이티드	테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
NZ743651A (en)	2015-12-09	2023-07-28	Univ Illinois	Benzothiophene-based selective estrogen receptor downregulators
ES2989988T3 (es)	2016-05-10	2024-11-28	C4 Therapeutics Inc	Degronímeros heterorocíclicos para la degradación de proteínas diana
WO2017197051A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	Amine-linked c3-glutarimide degronimers for target protein degradation
WO2017197046A1 (en)	2016-05-10	2017-11-16	C4 Therapeutics, Inc.	C3-carbon linked glutarimide degronimers for target protein degradation
CN109562113A (zh)	2016-05-10	2019-04-02	C4医药公司	用于靶蛋白降解的螺环降解决定子体
EA201990187A1 (ru)	2016-07-01	2019-07-31	Г1 Терапьютикс, Инк.	Антипролиферационные средства на основе пиримидина
WO2018081168A2 (en)	2016-10-24	2018-05-03	The Board Of Trustees Of The University Of Illinois	Benzothiophene-based selective mixed estrogen receptor downregulators
TWI823845B (zh)	2017-01-06	2023-12-01	美商G1治療公司	用於治療癌症的組合療法
WO2018148576A1 (en)	2017-02-10	2018-08-16	G1 Therapeutics, Inc.	Benzothiophene estrogen receptor modulators
CN110769822A (zh)	2017-06-20	2020-02-07	C4医药公司	用于蛋白降解的n/o-连接的降解决定子和降解决定子体
EP4455146A3 (en)	2017-06-29	2025-01-01	G1 Therapeutics, Inc.	Morphic forms of git38 and methods of manufacture thereof
CN120698983A (zh)	2018-12-20	2025-09-26	C4医药公司	靶向蛋白降解
JP7616794B2 (ja)	2019-07-07	2025-01-17	オレマファーマシューティカルズインク．	エストロゲン受容体アンタゴニストのレジメン
MX2022007659A (es)	2019-12-20	2022-07-19	C4 Therapeutics Inc	Compuestos de isoindolinona e indazol para la degradacion del receptor del factor de crecimiento epidermico (egfr).
MX2022010952A (es)	2020-03-05	2022-10-07	C4 Therapeutics Inc	Compuestos para la degradacion dirigida de brd9.
JP2023538517A (ja)	2020-08-05	2023-09-08	シーフォーセラピューティクス，インコーポレイテッド	Ｒｅｔの標的分解のための化合物
CN117940133A (zh)	2021-06-08	2024-04-26	C4医药公司	用于突变braf的降解的治疗剂
EP4565585A1 (en)	2022-08-03	2025-06-11	Bristol-Myers Squibb Company	Compounds for modulating ret protein
CN120530116A (zh)	2022-11-04	2025-08-22	百时美施贵宝公司	Ret-ldd蛋白抑制剂
JP2025540907A (ja)	2022-11-04	2025-12-17	ブリストル－マイヤーズスクイブカンパニー	Ｒｅｔ－ｌｄｄタンパク質分解誘導剤
WO2025006753A2 (en)	2023-06-30	2025-01-02	Merck Patent Gmbh	Heterobifunctional compounds for the degradation of kras protein

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ZA716118B (en) *	1970-10-05	1972-05-31	Richardson Merrell Inc	Contraception
ZA9510926B (en) *	1994-12-23	1996-07-03	Schering Ag	Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120263A0 (en) *	1996-02-28	1997-06-10	Pfizer	Combination therapy to prevent bone loss-progesterone and estrogen agonists
ATE206701T1 (de) *	1996-04-19	2001-10-15	American Home Prod	Östrogene verbindungen
US5747480A (en) *	1996-05-08	1998-05-05	American Home Products Corporation	Oral contraceptive

1998
- 1998-04-11 ID IDW20000811A patent/ID24568A/id unknown
- 1998-04-11 UA UA2000063196A patent/UA68365C2/uk unknown
- 1998-11-04 SK SK648-2000A patent/SK6482000A3/sk unknown
- 1998-11-04 ES ES98956525T patent/ES2246541T3/es not_active Expired - Lifetime
- 1998-11-04 DE DE69831605T patent/DE69831605T2/de not_active Expired - Lifetime
- 1998-11-04 AT AT98956525T patent/ATE304359T1/de not_active IP Right Cessation
- 1998-11-04 JP JP2000520119A patent/JP2001522798A/ja not_active Ceased
- 1998-11-04 PL PL98340623A patent/PL340623A1/xx unknown
- 1998-11-04 EP EP98956525A patent/EP1051179B1/en not_active Expired - Lifetime
- 1998-11-04 NZ NZ503890A patent/NZ503890A/xx unknown
- 1998-11-04 TR TR2000/01268T patent/TR200001268T2/xx unknown
- 1998-11-04 CN CN98810911A patent/CN1278732A/zh active Pending
- 1998-11-04 BR BR9813982-7A patent/BR9813982A/pt not_active Application Discontinuation
- 1998-11-04 EA EA200000492A patent/EA200000492A1/ru unknown
- 1998-11-04 IL IL13562198A patent/IL135621A0/xx unknown
- 1998-11-04 AU AU13031/99A patent/AU760540B2/en not_active Ceased
- 1998-11-04 CA CA002307210A patent/CA2307210A1/en not_active Abandoned
- 1998-11-04 GE GEAP19985364A patent/GEP20043290B/en unknown
- 1998-11-04 EE EEP200000211A patent/EE04092B1/xx not_active IP Right Cessation
- 1998-11-04 HR HR20000269A patent/HRP20000269A2/hr not_active Application Discontinuation
- 1998-11-04 DK DK98956525T patent/DK1051179T3/da active
- 1998-11-04 HU HU0100293A patent/HUP0100293A3/hu unknown
- 1998-11-04 CZ CZ20001661A patent/CZ294155B6/cs not_active IP Right Cessation
- 1998-11-04 WO PCT/US1998/023427 patent/WO1999024027A2/en not_active Ceased
- 1998-11-05 ZA ZA9810136A patent/ZA9810136B/xx unknown
- 1998-11-05 AR ARP980105591A patent/AR016667A1/es not_active Application Discontinuation
2000
- 2000-04-27 NO NO20002167A patent/NO20002167L/no not_active Application Discontinuation
- 2000-05-17 BG BG104451A patent/BG104451A/xx unknown
2003
- 2003-06-23 AU AU2003204896A patent/AU2003204896B2/en not_active Ceased

Also Published As

Publication number	Publication date
AU2003204896B2 (en)	2006-06-15
EP1051179A2 (en)	2000-11-15
HRP20000269A2 (en)	2000-12-31
CN1278732A (zh)	2001-01-03
CA2307210A1 (en)	1999-05-20
NZ503890A (en)	2002-08-28
BG104451A (en)	2000-12-29
DE69831605T2 (de)	2006-06-14
WO1999024027A2 (en)	1999-05-20
ZA9810136B (en)	2000-05-05
DK1051179T3 (da)	2005-10-31
AR016667A1 (es)	2001-07-25
CZ294155B6 (cs)	2004-10-13
EE200000211A (et)	2001-04-16
BR9813982A (pt)	2000-09-26
PL340623A1 (en)	2001-02-12
DE69831605D1 (de)	2005-10-20
HUP0100293A2 (hu)	2001-10-28
ES2246541T3 (es)	2006-02-16
EE04092B1 (et)	2003-08-15
EP1051179B1 (en)	2005-09-14
SK6482000A3 (en)	2000-11-07
NO20002167L (no)	2000-06-28
AU1303199A (en)	1999-05-31
ID24568A (id)	2000-07-27
EA200000492A1 (ru)	2000-10-30
IL135621A0 (en)	2001-05-20
CZ20001661A3 (cs)	2000-12-13
WO1999024027A3 (en)	1999-07-15
TR200001268T2 (tr)	2001-01-22
HUP0100293A3 (en)	2002-12-28
JP2001522798A (ja)	2001-11-20
ATE304359T1 (de)	2005-09-15
GEP20043290B (en)	2004-07-26
NO20002167D0 (no)	2000-04-27
AU760540B2 (en)	2003-05-15

Publication	Publication Date	Title
UA68365C2 (en)	2004-08-16	Peroral contraception by combination of anti-estrogen and progestin
US20020061875A1 (en)	2002-05-23	Anti-estrogen plus progestin containing oral contraceptives
US20110059928A1 (en)	2011-03-10	Graduated estrogen contraceptive
EP0912186B1 (en)	2002-03-06	Progestogen-anti-progestogen regimens
US6506390B2 (en)	2003-01-14	Progestogen-anti-progestogen regimens
BG62384B1 (bg)	1999-10-29	Прогестероново-антагонистични и антиестрогенови активнисъединения с общо приложение за женски контрацептиви
US20070004690A1 (en)	2007-01-04	Quadraphasis continuous graduated estrogen contraceptive
US7935691B2 (en)	2011-05-03	Extended cycle multiphasic oral contraceptive kit
CA2566811A1 (en)	2005-12-15	Compositions and methods for treatment of premenstrual dysphoric disorder
AU747710B2 (en)	2002-05-23	Progestogen-antiprogestogen regimens
RU2002107987A (ru)	2004-12-27	Фармацевтическая комбинация этинилэстрадиола и дроспиренона для использования в качестве контрацептива
CA2371635A1 (en)	2000-11-09	Use of antiprogestagens in combined therapy
MXPA00004610A (en)	2001-05-07	Progestogen-antiprogestogen regimens
HK1019305B (en)	2002-07-05	Progestogen-anti-progestogen regimens